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Abstract 
Background 
Low density lipoprotein cholesterol (LDL-C) levels are used to estimate cardiovascular 
disease (CVD) risk and to guide prescriptions. To circumvent the challenges of direct LDL-C 
measurement, guidelines recommend the use of Friedewald formula derived LDL-C levels. 
Despite reported limitations of this formula, its validity in sub-Saharan Africans has not been 
adequately investigated 
Objective 
To assess the validity of the Friedewald formula derived against directly (homogeneous) 
measured LDL-C in adult Cameroonians. 
Methods 
We reviewed the fasting lipid profiles of 2500 patients, performed between March 2012 and 
January 2016 using enzymatic colorimetric method (reference), at the Douala General 
Hospital laboratory. The Friedewald formula was used to calculate LDL-C from total 
cholesterol, high density lipoprotein cholesterol and triglyceride levels. Calculated LDL-C 
values were compared to the reference values, and clinical significance of differences between 
the two methods was assessed using total error allowable (TEa). 
Results 
The difference between means of calculated and the reference LDL-C values was neither 
statistically nor clinically significant (3.33±1.51 vs. 3.33±1.25 mmol/l; p=0.704). The 
calculated LDL-C correlated positively with the measured LDL-C value (r=0.749) and both 
methods showed a good agreement on Bland-Altman plot. Conversely, there was only 
moderate agreement (kappa=0.478, 95% CI: 0.455-0.502) between the two values in the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
stratification of cardiovascular risk according to the National Cholesterol Education 
Program/Adult Treatment Panel III. Consequently, 40.6% of the participants were 
misclassified.  
Conclusion 
Friedewald formula is technically accurate but has a modest clinical accuracy which can 
translate into a substantial misclassification of patients’ cardiovascular risk and subsequent 
inappropriate therapeutic decisions.  
Keywords: Low density lipoprotein cholesterol; Friedewald formula; direct homogenous 
assay; agreement; cardiovascular risk; sub-Saharan Africa; Cameroon  
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Introduction 
Cardiovascular diseases (CVD) continue to be a serious problem worldwide [1]. Cameroon 
like many other African countries is experiencing the epidemiological transition characterized 
by increasing CVD-related mortality [2]. Observational and interventional studies have 
established a causal relationship between low density lipoprotein cholesterol (LDL-C) level 
and atherosclerotic CVD [3]. LDL-C level, as calculated by the Friedewald formula (FF) in 
routine patient care, has a pivotal role in CVD risk estimation and reduction across clinical 
practice guidelines worldwide [4–6]. 
According to the FF, LDL-C level can be estimated from the difference between total 
cholesterol (TC) and the cholesterol content of other lipoprotein particles, namely high 
density lipoprotein (HDL-C) and very low density lipoprotein (VLDL-C), through the 
equation LDL-C (mmol/l) = TC - HDL-C –[Triglycerides (TG)/2.17], where TG/2.17 is an 
estimate of serum VLDL-C concentration [7]. This formula was introduced into clinical 
practice over four decades ago; because ultracentrifugation to directly measure LDL-C was 
time consuming, costly, and unavailable for routine clinical practice. Friedewald and 
colleagues however, recognized that the term TG/2.17 could not accurately estimate VLDL-C 
especially at triglycerides values> 4.52 mmol/l. Such inaccuracy could be tolerated because 
serum VLDL-C concentration is small relative to LDL-C concentration, but with the 
epidemics of other cardiovascular risk factors [8], such an assumption could jeopardize the 
standard of care offered to patients. Attempting to redress these problems, the expert panel of 
National Cholesterol Education Program in 1995 recommended the development of direct 
homogenous assay for precise and accurate measurement of LDL-C [9]. However, the direct 
homogenous assay method remains unavailable and expensive for patients, especially in low 
income countries [6]. Furthermore, studies have shown that FF can underestimate LDL-C 
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values when compared to the ultracentrifugation [10] or to the direct homogeneous assay [11], 
or to  overestimate it [12]. All these may lead either to failure to give medical attention to a 
deserving patient, or to needless and expensive polypharmacy, respectively. In the sub-
Saharan African population where CVD is now a major public health concern [13] the 
formula has remained in routine use with little scrutiny. Besides, studies have found 
differences in metabolism of lipids between Caucasians and Africans [14,15]. Despite the 
above, only studies with small sample size have attempted to validate the FF (which was 
established based on fasting lipid profiles of 448 Caucasians) [7] in Africans.  
In this study, we have used a larger sample to assess the validity of the Friedewald-calculated 
against the measured (by direct homogeneous assay) LDL-C in adult Cameroonians, by 
comparing the absolute mean values, assessing the continuous association, determining the 
level of agreement between estimated and measured LDL-C, and finally assessing the clinical 
significance of differences between estimated and measured LDL-C in clinical decision 
making. 
 
Methods 
Study design and setting 
In this study, we reviewed the records of fasting lipid profiles performed at the laboratory of 
Douala General Hospital (DGH). DGH is a reference healthcare teaching hospital located in 
the Littoral Region of Cameroon. The laboratory undergoes annual external and internal 
quality control and was accredited in 2012 (accreditation N
o
 ISO 15189-2012). Since March 
2012, the DGH laboratory has been systematically measuring LDL-C directly on a Roche-
Hitachi Cobas C311
® 
analyzer (Roche Diagnostics GmbH, Mannheim, Germany; Hitachi 
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High-Technology Corporation, Tokyo, Japan) using a colorimetric autoanalyzer kit which is 
Centers for Disease Control and Prevention (CDC)-certified, accurate and precise for lipid 
analysis. The same enzymatic colorimetric method were being used for total cholesterol, HDL 
cholesterol and triglycerides.   
Data collection 
We studied the fasting lipid profile records of patients managed at the Douala General 
Hospital from March 2012 to January 2016. All consecutive lipid profiles of patients aged 18 
years and above performed during the study period were included. Each patient’s record 
contained measured serum concentrations of each parameter of the lipid profile. Records were 
excluded if demographic data (age and gender) were missing, the lipid profile was 
incomplete, or the TG level was > 4.52 mmol/l. Individual LDL-C levels were then calculated 
using the Friedewald formula. Hypercholesterolemia was defined as serum total cholesterol > 
5.0 mmol/L, and hypertriglyceridemia as serum triglycerides level > 1.70mmol/l. 
Statistical analysis 
Data were analyzed using the R statistical software version 3.2.2 (The R Foundation for 
Statistical Computing, Vienna, Austria). Variables were summarized as mean and standard 
deviation, median and 25th-75th percentiles, and count and percentages. The Shapiro-Wilk W 
test was used to determine whether the LDL-C values were normally distributed based on 
probability threshold of p > 0.1. Skewness was assessed with the D’agostino test [16] and 
Kurtosis with the Anscombe-Glynn test [17]. 
Analysis of the variance, Kruskal-Wallis test, and chi square test were used to compare 
characteristics across gender. Measured LDL-C served as the reference for all comparisons. 
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Paired-sample t-test and Wilcoxon test were used to compare differences in means of 
measured and calculated LDL-C concentrations overall and within subgroups.  
The continuous association between measured and calculated LDL-C was assessed using the 
Pearson and Spearman correlation tests. Linear regression models were used to derive the 
regression coefficients, which helped us to predict the reference (measured) values from the 
calculated LDL-C values. Adjusted coefficient of determination (adjusted R-squared) was 
calculated to assess the performance of models. Assessment of systematic bias was judged 
using Bland and Altman plots [18] implemented with the use of ‘Research Methods’ package 
of R. Agreement in stratifying cardiovascular risk was assessed using Kappa statistics [19] 
with 95% confidence interval (95%CI) derived from bootstrap percentile methods, based on 
2000 replications. We used the NCEP/ATP III, 2002, cut off points for cardiovascular risk 
stratification to compare the level of agreement between the two methods in categorizing 
participants in various risk groups.  
To gauge the clinical importance of statistically significant differences between measured and 
estimated LDL-C, we used the total allowable error (TEa) [20] which was based on within- 
and between-subject variations. The mean of the calculated LDL-C was then compared with 
the mean of measured LDL-c. The former had to fall within clinical range of reference mean 
± TEa. To get the TEa, we calculated the percentage difference as: 100*[(Calculated–
Measured)/Measured LDL-C] and multiplied it by the mean of the calculated LDL-C. If the 
mean of the calculated was out of the range (reference mean ± TEa), the difference was 
considered clinically significant, which means that it could cause potentially harmful clinical 
decisions. 
Ethical approval 
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This study was approved by the Institutional Ethics Committee for Research on Human 
Health of the University of Douala (N°IEC-UD/447/02/2016/T). Administrative clearance 
was obtained from the authorities of the DGH. Confidentiality, anonymity and privacy of all 
records were guaranteed at all levels of this study by using only specific codes.  
 
Results 
Characteristics of participants and lipid profiles 
Of the 2500 records included, 1254 (50.2%) were from men. The mean age of the participants 
was 54.1 years. Mean values of lipid profile parameters and comparison between men and 
women is shown in Table 1. In all 58.2% of the sample had hypercholesterolemia while 
16.5% had hypertriglyceridemia, with prevalence higher in women than in men for 
hypercholesterolemia (p<0.001), but the opposite for hypertriglyceridemia (p<0.001), Table 1. 
Table 1: General characteristics of participants overall and by gender 
Characteristics Overall Men Women p-value* 
N (%) 2501 (100) 1254 (50.2) 1246 (49.8)  
Age, years 54.1 (12.6) 53.7 (12.3) 54.5 (12.9) 0.104 
Total cholesterol, mmol/l 5.40 (1.49) 5.21 (1.57) 5.58 (1.38) <0.001 
HDL-C, mmol/l 1.45 (0.90) 1.37 (0.94) 1.61 (0.86) <0.001 
Triglycerides, mmol/l 1.24 (0.81) 1.33 (0.91) 1.15 (0.68) <0.001 
Total cholesterol >5.0 mmol/l, % 58.2 52.5 64.0 <0.001 
Triglycerides >1.70 mmol/l, % 16.5 19.4 13.6 <0.001 
*P-value for comparison between men and women. 
Data are presented as mean (standard deviation), unless stated otherwise; HDL-C: high density 
lipoprotein-cholesterol. 
Comparison of measured versus calculated LDL-C 
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Figure 1 shows a leptokurtic distribution of measured and calculated LDL-C. Measured LDL-
C curve overlapped with estimated LDL-C curve, suggesting similar variability of LDL-C 
values from the mean for both methods. This was similar within genders. The non normal 
distribution was confirmed by the Shapiro Wilk test p-values < 0.0001 overall and within 
genders (Table 2). The difference between means of calculated and measured LDL-C values 
was not statistically significant (Table 2).  
 
 
Figure 1: Distribution curves for Measured LDL-C and calculated LDL-C for the whole 
study population. Measured LDL-C is represented by solid black line, and calculated-LDL-C 
is represented by broken blue line. 
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Table 2: Mean difference and correlation between measured and estimated LDL-C 
LDL-C: Low density lipoprotein cholesterol,   CI: Confidence interval, 
*
p-value men vs. 
women; 
**
p-value measured vs. estimated LDL-C 
Assessment of the association between measured and estimated 
LDL-C 
We found a positive correlation between estimated and measured LDL-C values in the overall 
sample and within genders (Table 2 and Figure 2).The linear regression equation linking the 
calculated to the measured LDL-C values in the overall sample, men and women were 
respectively: calculated LDL-C = 0.901*measured LDL-C + 0.337, calculated LDL-C = 
0.901*measured LDL-C + 0.307, and calculated LDL-C= 0.897*measured LDL-C + 0.379 
with respective adjusted R
2 
of: 0.560, 0.577, and 0.534. 
Characteristics Overall Men Women p-value
* 
Measured LDL-C (mmol/L) 
Mean (SD) 3.33 (1.25) 3.25 (1.35) 3.41 (1.15) 0.001 
Shapiro p <0.0001 <0.0001 <0.0001  
Coefficient of variation (%) 37.7 41.5 33.6  
Calculated LDL-C (mmol/L) 
Mean (SD) 3.33 (1.51) 3.23 (1.60) 3.44 (1.40)  
Shapiro p <0.0001 <0.0001 <0.0001  
Coefficient of variation (%) 45.3 49.5 40.9  
Measured – Calculated LDL-C (mmol/L) 
Mean (95%CI) -0.008 [-0.047-0.032] 0.014 [-0.044-0.072] -0.029 (-0.083-0.025)  
Paired t-test
** 
0.704 0.646 0.288  
Correlation coefficient     
Pearson (95% CI) 0.749 (0.731-0.765) 0.760 (0.735-0.782) 0.731 (0.704-0.756)  
Spearman 0.848 0.846 0.845  
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Figure 2: Linear regression curves showing the continuous association of measured with 
calculated LDL-C for the whole study population. 
The dotted diagonal line is the line of perfect agreement, and the blue line is the regression 
line between calculated and measured LDL-C in our study popualtion. Adjusted R-squared is 
the adjusted coefficient of determination. 
 
Bland and Altman plots of differences between measured and estimated LDL-C values plotted 
on the y-axis and the mean of these values on the x-axis were used to assess systematic bias in 
the overall sample. Most of the plotted points lied around the line of perfect agreement (light 
dotted blue line through zero). The solid green line which is the difference between the two 
methods (mean bias), overlaps with the line of perfect agreement. This was also true in the 
two subgroups, suggesting a good technical agreement between the two methods. 
Nonetheless, there were multiple outliers in negative and positive regions of the graph 
signifying probable discordance between the two methods at extreme LDL-C values (Figure 
3). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Figure 3: Bland-Altman plot of agreement between estimated and measured LDL-C for 
the overall sample. 
SD: standard deviation. +2SD and -2SD are the upper and lower limits of agreement. The 
solid green line is the difference between the 2 methods (mean bias); the lighter dotted blue 
line through zero is the line used to assess the discrepancy of the observed mean difference (it 
is a line of perfect agreement between the two measurements), and the shaded zone represent 
limits of agreement (within 2 SD). The linear curve of best fit is also shown (broken 
superimposed curve).  
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Table 3: Agreement between estimated and measured LDL-C in classifying patient’s 
cardiovascular risk categories (NCEP/ATPIII), overall and by gender 
 Categories of measured LDL Kappa 
Categories of Calculated 
LDL-C 
<2.58 ]2.58 to 
3.35] 
]3.35 to 
4.11]  
]4.11 to 
4.88] 
>4.88  
Overall population      0.478 (95%CI: 0.455-
0.502) 
<2.58 528 
(79.6) 
     
]2.58 to 3.35]  377 (54.4)     
]3.35 to 4.11]   254 (47.2)    
]4.11 to 4.88]    159 (44.2)   
>4.88     167 
(67.9) 
 
Men      0.478 (95%CI: 0.443-
0.511) 
<2.58 304 
(80.4) 
     
]2.58 to 3.35]  168 (51.1)     
]3.35 to 4.11]   126 (47.9)    
]4.11 to 4.88]    75 (44.6)   
>4.88     78 
(67.2) 
 
Women      0.475 (95%CI: 0.443 to 
0.509) 
<2.58 224 
(78.6) 
     
]2.58 to 3.35]  209 (57.4)     
]3.35 to 4.11]   128 (46.5)    
]4.11 to 4.88]    84 (43.7)   
>4.88     89 
(68.5) 
 
Normotriglyceridemia      0.472 (95%CI: 0.444 to 
0.500) 
<2.58 433 
(78.4) 
     
]2.58 to 3.35]  344 (56.0)     
]3.35 to 4.11]   219 (47.6)     
]4.11 to 4.88]    121 (42.2)   
>4.88     119 
(68.4) 
 
Hypertriglyceridemia      0.497 (95%CI: 0.438 to 
0.555) 
<2.58 95 
(85.6) 
     
]2.58 to 3.35]  33 (41.8)     
]3.35 to 4.11]   35 (44.9)    
]4.11 to 4.88]    38 (52.0)   
>4.88     48 
(66.7) 
 
Data are presented as counts (percentage) 
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Overall the level of agreement between the two measurements in cardiovascular risk 
stratification was only moderate; kappa (95% CI) was 0.478 (0.455-0.502) and similar in men 
and women. As a consequence, up to 1015 participants (40.6%) were misclassified by 
calculated LDL-C, with about half of them (20.9%) misclassified into higher risk group and 
19.7 % into lower risk group compared to measured LDL-C. The observed agreement 
between estimated and measured LDL-C was high at extreme LDL-C values. 79.6% for LDL-
C <2.58 mmol/l and 67.9 % for LDL-C >4.88 mmol/l (Table 3). Between these levels, the 
level of agreement decreased as the LDL-C level increases (Table 3). By status for 
hypertriglyceridemia, the agreement statistic was kappa 0.472 (95%CI 0.444-0.500) for 
participants with normotriglyceridemia, and 0.497 (0.438-0.555) among those with 
hypertriglyceridemia. When participants were grouped by quarters of total cholesterol, the 
agreement was 0.392 (0.309 to 0.471) in the bottom quarter (TC<4.44 mmol/l) and 0.282 (0.226 to 
0.340) in the top quarter (TC>6.28 mmol/l). 
Using the TEa, the difference between the measured and the calculated LDL-C values was not 
clinically significant, either in the overall population or in the two genders (Table 4). 
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Table 4: Clinical significance based on total error allowable 
Subgro
up 
measurem
ent 
N 
Mea
n 
(SD) 
 S
D 
% 
differen
ce 
Statistica
l 
significa
nce 
TE
% 
 Mean*T
E% 
Allowabl
e range 
Clinical 
significa
nce 
         
mi
n 
ma
x  
Overall Measured 
250
1 
3.33 
1.2
5 
0 0.704 11.9 0.40 
2.9
0 
3.7
0 
Not 
significan
t 
 
Calculated 
250
1 
3.33 
1.5
1 
0.2 
      
Men Measured 
125
4 
3.25 
1.3
5 
0 0.646 11.9 0.39 
2.9
0 
3.6
0 
Not 
significan
t 
 
Calculated 
125
4 
3.23 
1.6
0 
-0.4 
      
Women Measured 
124
6 
3.41 
1.1
5 
0 0.288 11.9 0.41 
3.0
0 
3.8
0 
Not 
significan
t 
 
Calculated 
124
6 
3.44 
1.4
1 
0.9 
      
TE: Total error 
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Discussion 
Worldwide guidelines recommend Friedewald-estimated LDL-C for cardiovascular risk 
assessment and therapeutic target [4–6]. In this study, we found that the mean difference 
between Friedewald-estimated and measured LDL-C was neither statistically nor clinically 
significant. There was a positive association between the two methods and they also displayed 
good agreement on Bland-Altman plot. Nonetheless, the two methods showed only moderate 
agreement in cardiovascular risk stratification according to the NCEP-ATPIII. 
Many similar studies have been carried out on this subject, mostly in developed countries. In 
the current study, we showed that the mean difference between estimated and measured LDL-
C was not significant, regardless of the gender. Our  finding are congruent with those of few 
other studies [21,22]. Nevertheless, many studies have shown significant differences in the 
mean values of Friedewald-estimated and measured LDL-C [11,23–26]. The accuracy of the 
result obtained by the FF is dependent on a number of factors, namely 9-12 hours fasting 
prerequisite, analysis of TC, HDL-C and TG as well as the disease status of an individual. 
Thus, due respect of these prerequisite may explain the differences observed.  
We found a strong correlation of 0.749 between the two methods. Many studies have also 
shown a strong correlation between estimated and measured LDL-C [27]. Even with the 
strong positive correlation, the actual test of technical accuracy applicable was the Bland-
Altman plots which showed a good agreement between the two methods. On the contrary, 
most of the above mentioned studies have shown that Friedewald-estimated LDL-C 
underestimates or overestimates cardiovascular risk, which was displayed by positive or 
negative mean bias on Bland-Altman plot respectively. The difference between those studies 
and ours can be explained by differences in socio-demographic background, study setting, 
study design and even sample size. Whether the type of food eaten by our participants could 
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have been the reason behind our differences as noted by Fukuyama et al. [27] in Japan could 
not be ascertained in this study.  
While it is generally unlikely that different methods will exactly agree, the question should be 
whether the magnitude of any bias affects clinical judgment. Correctly estimating patients’ 
LDL-C is invaluable as reporting a wrong value can convey a wrong message about 
cardiovascular risk leading to inappropriate treatment. The NCEP/ATP III cut-off 
concentrations are important parameters in therapeutic decisions. When we used these cut-off 
points to stratify participants’ cardiovascular disease risk, we found that overall, the level of 
agreement between the two methods was only moderate (kappa=0.478), with a consequent 
misclassification in 40.6% patients by estimated LDL-C. This implies that estimated LDL-C 
in our population may overestimate or underestimate about two out of every five patient’s 
cardiovascular risk. It should however be noted that with the advent of the 2013 American 
College of Cardiology/American Heart Association guidelines that are more focused on risk 
groups rather than multiple LDL-C categories [28], the problem of misclassification is 
currently of very limited interest. 
Our findings are however likely to be of greater relevance because patients managed in a 
reference hospital usually have other cardiovascular risk factors, hence overestimating their 
risk of CVD may leads to polypharmacy which may further complicate their pre-existing 
condition. On the contrary, underestimating their risk may undermine, and sometime would 
deny medical attention to the deserving patients in our population. This is especially 
important in our population where the rising trend of other cardiovascular comorbidities such 
as hypertension and diabetes is already established [29]. 
We acknowledge the following limitations that should be considered when generalizing the 
results. Firstly, FF was proposed to be used for epidemiological studies and not for diagnosis 
or following-up of CVD patients as in our study. However, worldwide recommendations have 
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prescribed FF to be used for such purposes [4–6]. Secondly, our study examined a single 
measurement of LDL-C, which is the common practice in clinical decision-making, however 
guidelines also advocate serial measurements to establish greater accuracy or assess changes 
in serum LDL-C levels following intervention [4,6]. Other potential limitations pertain to 
confounders that may influence the calculated or the directly-measured LDL-C. For instance, 
calculated LDL-C may be influenced by HDL-C measurement errors or by elevated Lipoprotein (a), 
whereas direct homogeneous LDL-C measurement may have been influenced by errors in samples 
from dyslipidemic patients or from diseased patients in our study population. 
 
Conclusions 
Compared to the direct homogeneous measurement of LDL-C, the Friedewald formula is 
technically accurate but its clinical accuracy is modest; as a consequence, Friedewald-
estimated LDL-C may misclassify cardiovascular risk of two out of every five patients. This 
conveys a potential wrong clinical and epidemiological decisions, in terms of individual CVD 
risk stratification and therapeutic decisions. Thus, with the current trend of cardiovascular 
disease in our setting, there is need to use Friedewald-estimated LDL-C with caution 
especially when accuracy matters most.  
 
Acknowledgements 
The 2HD Research Network is supported by a Cruddas Link Fellowship (SPC), Tseu Medical 
Institute, Harris Manchester College, University of Oxford, UK. We are also grateful to the 
laboratory staff of the Douala General Hospital for their assistance during this study. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Funding 
This research did not receive any specific grant from funding agencies in the public, 
commercial or not-for-profit section. 
 
Authors’ contributions 
SPC: study conception and design, data collection and interpretation, draft and review of the 
manuscript   
TM: study conception and design, data collection and interpretation, draft of the manuscript 
JPD: data collection and review of the manuscript   
CAD: data analysis and review of manuscript 
YMD: data analysis and drafting of manuscript  
ES: study conception, review of the manuscript 
APK: study design, data analysis and interpretation, review of the manuscript 
All authors made significant intellectual contributions and have read, reviewed, and approved 
the final manuscript. 
 
Competing interest 
The authors declare no competing interest relevant to this article. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
References 
1.  World Health Organization | Cardiovascular diseases (CVDs). 
http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 19 Dec 2016. 
2.  Kengne AP, Mayosi BM. A snapshot of cardiovascular diseases in Africa in the new 
millennium. Cardiovasc J Afr. 2013;24:104‑ 105.  
3.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in 
incidence of coronary heart disease. JAMA. 1984;251:351‑ 364.  
4.  Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 
Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and 
Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. 
Can J Cardiol. 2013;29:151‑ 167.  
5.  European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, 
Catapano AL, De Backer G, Graham I, Taskinen M-R, et al. ESC/EAS Guidelines for 
the management of dyslipidaemias: the Task Force for the management of 
dyslipidaemias of the European Society of Cardiology (ESC) and the European 
Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769‑ 1818.  
6.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) Final Report. Circulation. 2002;106:3143‑ 3421.  
7.  Friedewald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-
Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative 
Ultracentrifuge. Clin Chem. 1972;18:499‑ 502.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
8.  Ogunmola OJ, Olaifa AO, Oladapo OO, Babatunde OA. Prevalence of cardiovascular 
risk factors among adults without obvious cardiovascular disease in a rural community 
in Ekiti State, Southwest Nigeria. BMC Cardiovasc Disord. 2013;13:89.  
9.  Bachorik PS, Ross JW. National Cholesterol Education Program recommendations for 
measurement of low-density lipoprotein cholesterol: executive summary. The National 
Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin 
Chem. 1995;41:1414‑ 1420.  
10.  Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, et al. 
Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and 
treatment implications. J Am Coll Cardiol. 2013;62:732‑ 739.  
11.  Warade JP, Dahake H, Kavitha R. Comparison between direct estimation of LDL and 
Friedewald’s formula. Int Arch Integr Med. 2016;3:10‑ 17.  
12.  Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a 
critical assessment of direct measurement by homogeneous assays versus calculation. 
Clin Chem. 2002;48:236‑ 254.  
13.  Mocumbi AO. Lack of focus on cardiovascular disease in sub-Saharan Africa. 
Cardiovasc Diagn Ther. 2012;2:74‑ 77.  
14.  Ellman N, Keswell D, Collins M, Tootla M, Goedecke JH. Ethnic differences in the 
association between lipid metabolism genes and lipid levels in black and white South 
African women. Atherosclerosis. 2015;240:311‑ 317.  
15.  Ho KJ. Cholesterol metabolism in caucasians and East African Masai. Proc Inst Med 
Chic. 1970;28:78.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
16.  D’agostino RB, Belanger A, D'agostino Jr RB. A Suggestion for Using Powerful and 
Informative Tests of Normality. Am Stat. 1990;44:316‑ 321.  
17.  Anscombe FJ, Glynn WJ. Distribution of the kurtosis statistic b2 for normal samples. 
Biometrika. 1983;70:227‑ 234.  
18.  Bland JM, Altman DG. Statistical methods for assessing agreement between two 
methods of clinical measurement. Lancet. 1986;1:307‑ 310.  
19.  McHugh ML. Interrater reliability: the kappa statistic. Biochem Medica. 
2012;22:276‑ 282.  
20.  Biologic Variation Database, the 2014 Update - 
Westgard.https://www.westgard.com/biodatabase-2014-update.htm. Accessed 19 Dec 
2016. 
21.  Knopfholz J, Disserol CC, Diniz S, Schirr FL, Streisky L, Takito LL, et al. Validation of 
the Friedewald Formula in Patients with Metabolic Syndrome. Cholesterol. 
2014;2014:e261878.  
22.  Bimenya G, Kasolo J, Okwi A, Othieno E, Ochieng J, Kalule B, et al. Determination of 
LDL-cholesterol: direct measurement by homogeneous assay versus Friedewald 
calculation among Makerere University undergraduate fasting students. Int J Biol Chem 
Sci. 2010;4:464-470. 
23.  Tremblay AJ, Morrissette H, Gagné J-M, Bergeron J, Gagné C, Couture P. Validation of 
the Friedewald formula for the determination of low-density lipoprotein cholesterol 
compared with beta-quantification in a large population. Clin Biochem. 
2004;37:785‑ 790.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
24.  Boshtam M, Ramezani MA, Naderi G, Sarrafzadegan N. Is Friedewald formula a good 
estimation for low density lipoprotein level in Iranian population? J Res Med Sci Off J 
Isfahan Univ Med Sci. 2012;17:519‑ 522.  
25.  Chaudhari RK, Rajendra KC, Khan SA, Lal Das BK, Majhi S, Lamsal M, et al. 
Friedewald’s Method underestimates LDL-Cholesterol even at Lower Range of 
Triglyceride. Res J Pharm Biol Chem Sci. 2015;6:787.  
26.  Kapoor R, Chakraborty M, Singh N. A Leap above Friedewald Formula for Calculation 
of Low-Density Lipoprotein-Cholesterol. J Lab Physicians. 2015;7:11‑ 16.  
27.  Fukuyama N, Homma K, Wakana N, Kudo K, Suyama A, Ohazama H, et al. Validation 
of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol. J Clin Biochem 
Nutr. 2008;43:1‑ 5.  
28.  Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH,  et al. 
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce 
Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2014;129:S1-S45.  
29.  Echouffo-Tcheugui JB, Kengne AP. Chronic non-communicable diseases in Cameroon - 
burden, determinants and current policies. Glob Health. 2011;7:44.  
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Highlights 
 Friedewald formula accurately estimates LDL cholesterol in Cameroonians 
 Friedewald-calculated LDL cholesterol correlates well with measured LDL 
cholesterol 
 Using Friedewald formula may however misclassify the CV risk of 40% of 
patients 
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